-+ 0.00%
-+ 0.00%
-+ 0.00%

Absci Doses Participants In Phase 1/2a HEADLINE Trial Of ABS-201

Benzinga·12/04/2025 13:07:34
Listen to the news

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci's generative AI platform.

The Phase 1/2a clinical trial will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ABS-201. Interim data are expected in the second half of 2026.